Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05658757 · ClinicalTrials.gov registry record · NA
Preliminary Effect of Food Processing and Sweeteners on Glycemic and Metabolic Measures
A NA study of Blood Pressure and Dietary Habits, sponsored by University of California, Irvine.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT05658757: Completed NA study of Blood Pressure and Dietary Habits, sponsored by University of California, Irvine.
NCT05658757 is a NA study of Blood Pressure and Dietary Habits that has completed, run by University of California, Irvine. The registered enrollment target is 15 participants, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05658757, a NA study of Blood Pressure and Dietary Habits, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The average adult in the US consumes over 1/3 of a cup of sugar each day, or nearly 300 calories worth, with the primary sources being from beverages, desserts and sweet snacks, candy, additions to beverages, and foods such as breakfast cereals. This is a risky health behavior, as high added sugar intake relates to higher risk of gaining weight, blood sugar disorders such as type 2 diabetes, plus heart disease and various cancers. Thus, high added sugar intake is problematic, and something in need of reducing. Therefore, the investigators are proposing to test how commercial foods sweetened with a new, FDA approved rare sugar with net zero calories (allulose), that is derived from dried fruits, brown sugar, and maple syrup may impact added sugar intake and usual blood sugar levels. The investigators are doing this by a randomized trial, in which the investigators will recruit participants with abnormal blood sugars (prediabetes or diabetes) or higher metabolic risk (bigger waist and elevated blood pressure or blood cholesterol) and ask them in random order to include foods in their usual dietary intake that are sweetened by regular sugars (regular sugar), foods that are sweetened by the zero calorie rare sugar allulose (low added sugar), or low added sugar intake by higher intake of fresh fruits and minimally processed and sweetened foods in place of usual sweetened foods. The investigators will measure their usual blood sugar levels for each of these 3 different 2- week periods with a blood glucose monitor, along with what they eat each of those periods, their blood pressure, and how the different dietary approaches impact how they feel.
Primary Outcome
Measured via Blinded Continuous Glucose Monitoring (CGM). We will collect CGM data over the course of the study during each of the three, 14-day periods as the primary clinical measure. This is an apt measure that is meaningful and interpretable across the spectrum of glycemic/metabolic abnormality to frank type 2 diabetes. The inherent major influence of CV is postprandial glucose, which is meaningful across the same spectrum for disease risk. We will use the Abbott Freestyle Libre Pro system.
Conditions Studied
Interventions
- OTHER Regular sweetened commercial foods
- OTHER Allulose sweetened commercial foods
- OTHER Whole and minimally processed and sweetened foods
Study Locations (1)
California
- University of California, Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-11-09 |
| Est. Completion | 2023-04-19 |
| Phase | NA |
What the finished NCT05658757 record still lists
NCT05658757 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 287-participant average among 101 other Blood Pressure trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Blood Pressure appearing as the primary indexed condition, and to 3 interventions - of which Regular sweetened commercial foods is the first listed.
NCT05658757 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05658757 about?
NCT05658757 is a clinical study titled "Preliminary Effect of Food Processing and Sweeteners on Glycemic and Metabolic Measures". The average adult in the US consumes over 1/3 of a cup of sugar each day, or nearly 300 calories worth, with the primary sources being from beverages, desserts and sweet snacks, candy, additions to beverages, and foods such as breakfast cereals. This is a risky health behavior, as high added sugar i...
What is the current status of trial NCT05658757?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-11-09. Estimated completion is 2023-04-19.
What conditions does trial NCT05658757 study?
This clinical trial studies the following conditions: Blood Pressure, Dietary Habits, Blood Sugar; High.
What interventions are being tested in trial NCT05658757?
The interventions under investigation include: Regular sweetened commercial foods (OTHER), Allulose sweetened commercial foods (OTHER), Whole and minimally processed and sweetened foods (OTHER).
Who is sponsoring clinical trial NCT05658757?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05658757 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Pressure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05658757's enrollment target sits among peer trials
15 92nd of 101 higher than 8 of 101 other Blood Pressure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Pressure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Cocooned Moms Study
RECRUITING · NA
-
The GUARDIAN Trial
RECRUITING · NA
-
The Venous Distension Reflex and Orthostatic Hypertension
RECRUITING · NA
-
Breaking up Prolonged Sedentary Behavior to Improve Cardiometabolic Health
RECRUITING · NA
-
The Effect of Transcutaneous Stimulation on Blood Pressure in Spinal Cord Injury (SCI)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI